MAP2K7 and melanoma: Based on these findings, IMspire 170, a phase 3 trial, randomized 446 patients with unresectable stage III/IV BRAF-wildtype melanoma to receive either the MEK inhibitor cobimetinib plus atezolizumab, or the anti-PD-1 monoclonal antibody pembrolizumab alone [83].